Hironori Kanda

R&D Division
Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

In Reply to "Letter Regarding 'Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial'".

In Reply to "Letter Regarding 'Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial'".

Journal: Kidney international reports

Published: May 17, 2022

Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial.

Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial.

Journal: Journal of the Endocrine Society

Published: December 22, 2021

Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial.

Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial.

Journal: Kidney international reports

Published: April 23, 2021

Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients.

Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients.

Journal: Kidney international reports

Published: January 26, 2021

Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.

Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.

Journal: American journal of nephrology

Published: January 25, 2021

Redox Signaling and Reactive Sulfur Species to Regulate Electrophilic Stress

Redox Signaling and Reactive Sulfur Species to Regulate Electrophilic Stress

Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

Published: September 04, 2020

Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia.

Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: May 27, 2020

Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study).

Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study).

Journal: Kidney international reports

Published: February 07, 2020

Randomized Comparison Study of Novel Recombinant Human Antithrombin Gamma and Plasma-Derived Antithrombin in Healthy Volunteers.

Randomized Comparison Study of Novel Recombinant Human Antithrombin Gamma and Plasma-Derived Antithrombin in Healthy Volunteers.

Journal: Clinical drug investigation

Published: September 08, 2019

Bardoxolone methyl: drug development for diabetic kidney disease.

Bardoxolone methyl: drug development for diabetic kidney disease.

Journal: Clinical and experimental nephrology

Published: August 11, 2019

Nrf2 activator for the treatment of kidney diseases.

Nrf2 activator for the treatment of kidney diseases.

Journal: Toxicology and applied pharmacology

Published: June 28, 2018

S-mercuration of cellular proteins by methylmercury and its toxicological implications.

S-mercuration of cellular proteins by methylmercury and its toxicological implications.

Journal: The Journal of toxicological sciences

Published: September 23, 2014

Showing 1-12 of 15

Last Updated: 09/26/2026